Non-Injectable Insulin Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The non-injectable insulin market size has grown rapidly in recent years. It will grow from $1.92 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to patient compliance improvement, addressing needle phobia, quality of life enhancement, ease of administration, and stable blood glucose control.

The non-injectable insulin market size is expected to see rapid growth in the next few years. It will grow to $3.17 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to continued patient compliance emphasis, persistent needle phobia solutions, further quality of life improvements, continuous safety enhancement, and reduced infection and injury risks. Major trends in the forecast period include technological advancements, evolution of technological solutions, digital health integration, nanotechnology applications, and combination therapies.

The growing prevalence of obesity and diabetes is projected to boost the growth of the non-injectable insulin market in the coming years. Obesity is defined as the excessive accumulation of body fat, typically resulting from an imbalance between calorie intake and energy expenditure, while diabetes mellitus is a collection of metabolic disorders characterized by prolonged high blood sugar levels. Non-injectable insulin is utilized to manage diabetes and obesity, as it can improve treatment adherence by overcoming barriers to insulin therapy, potentially aid in weight management, and offer more convenient treatment alternatives. For instance, in 2022, the World Heart Federation, a Switzerland-based NGO, reported that global obesity rates are expected to rise significantly, with approximately 2.3 billion individuals, including children and adults, facing overweight and obesity in 2021, a figure projected to increase to 2.7 billion by 2025. Additionally, an April 2023 report from the British Diabetic Association, a UK-based diabetes charity, indicated that there are 4.3 million people living with diabetes in the UK, with over 2.4 million at high risk of developing type 2 diabetes. The registration figures for 2021-22 showed an increase of 148,951 compared to the prior year. Thus, the escalating issues of obesity and diabetes are driving the growth of the non-injectable insulin market.

Major companies in the non-injectable insulin market are focusing on innovative drug delivery technologies, such as needle-free oral insulin sprays, to enhance the lives of individuals managing diabetes with multiple insulin injections. Needle-free insulin sprays offer a painless alternative for regulating blood glucose levels, providing a convenient option by allowing doses to be sprayed directly into the mouth. For example, NiedlFree Technologies introduced Ozulin, an oral insulin spray, in November 2023. Ozulin aims to offer a user-friendly solution for individuals with diabetes, especially those who may struggle with traditional injectable insulin methods. If approved, Ozulin could revolutionize diabetes management by offering a more convenient and pain-free alternative to insulin injections.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition merges Abbott's proficiency in continuous glucose monitoring with Bigfoot's smart insulin management systems, bolstering Abbott's standing as a leader in comprehensive diabetes care. The acquisition aligns with Abbott's dedication to advancing connected solutions for precise diabetes management. Bigfoot Biomedical Inc., a US-based medical technology company, specializes in intelligent insulin administration systems for diabetes care.

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited.

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-injectable insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-injectable insulin market consists of sales of oral insulin, inhaled insulin, nasal insulin, carrier agents, and stabilizers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Non-injectable insulin, a type of insulin that doesn't require injection for administration, presents an innovative approach to diabetes management, aiming to enhance convenience and patient compliance. These non-injectable forms of insulin offer alternatives to traditional injections, potentially improving the overall quality of life for individuals with diabetes. They come in various forms, such as pills, sprays, and other delivery mechanisms, providing flexibility and ease of use for patients.

Synthetic insulin and semi-synthetic insulin are the two primary types of non-injectable insulin. Synthetic insulin is artificially produced through biotechnological methods, offering precise control over its composition and properties. This type of insulin can be tailored to meet specific patient needs and preferences. Semi-synthetic insulin is derived from natural sources but undergoes chemical modifications to enhance its stability, efficacy, or other desirable characteristics. Non-injectable insulin products are distributed through various channels, including hospital pharmacies, online pharmacies, and drug stores, ensuring accessibility for patients worldwide. These innovative insulin formulations represent a significant advancement in diabetes care, providing patients with additional options for managing their condition effectively while reducing the burden of frequent injections.

The non-injectable insulin market research report is one of a series of new reports that provides non-injectable insulin market statistics, including non-injectable insulin industry global market size, regional shares, competitors with a non-injectable insulin market share, detailed non-injectable insulin market segments, market trends and opportunities, and any further data you may need to thrive in the non-injectable insulin industry. This non-injectable insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.